Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other financing activities (2016 - 2018)

Vanda Pharmaceuticals' Other financing activities history spans 7 years, with the latest figure at $2.7 million for Q1 2018.

  • For Q1 2018, Other financing activities rose 20.69% year-over-year to $2.7 million; the TTM value through Mar 2018 reached $5.7 million, down 42.55%, while the annual FY2017 figure was $5.3 million, 32.25% down from the prior year.
  • Other financing activities for Q1 2018 was $2.7 million at Vanda Pharmaceuticals, up from $81000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $5.9 million in Q3 2016 and bottomed at -$513000.0 in Q3 2015.
  • The 5-year median for Other financing activities is $941000.0 (2016), against an average of $1.6 million.
  • The largest annual shift saw Other financing activities skyrocketed 122300.0% in 2014 before it crashed 91.71% in 2015.
  • A 5-year view of Other financing activities shows it stood at $2.4 million in 2014, then soared by 67.16% to $4.1 million in 2015, then crashed by 81.67% to $750000.0 in 2016, then crashed by 89.2% to $81000.0 in 2017, then skyrocketed by 3191.36% to $2.7 million in 2018.
  • Per Business Quant, the three most recent readings for VNDA's Other financing activities are $2.7 million (Q1 2018), $81000.0 (Q4 2017), and $768000.0 (Q3 2017).